Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX43 + HLX07
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX43 + HLX07 is a combination therapy developed by Shanghai Henlius Biotech for the treatment of advanced or metastatic colorectal cancer. HLX43 is a humanized anti-PD-L1 antibody-drug conjugate (ADC) that utilizes a novel DNA topoisomerase I (topo I) inhibitor payload with a drug-antibody ratio (DAR) of 8. It is designed to provide dual anti-tumor activity through immune checkpoint blockade and payload-mediated cytotoxicity. HLX07 is a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), engineered for lower immunogenicity and higher target affinity compared to cetuximab. This combination is currently being evaluated in Phase 1b/2 clinical trials for patients who have failed or are intolerant to standard first-line therapies.
- Other names
- HLX43 in combination with HLX07HLX-43 in combination with HLX07HLX 43 in combination with HLX07Anti-PD-L1 ADC + Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection
02
Targets
TOP1 (DNA Topoisomerase I)EGFR T790M (Epidermal growth factor receptor T790M mutant)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on HLX43 + HLX07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX43 + HLX07.